Cartesian Therapeutics announces additional retreatment data for Descartes-08 in myasthenia gravis patients
RNAC•Descartes-08 showed a mean 6.6-point MG-ADL reduction 12 months after retreatment, with a median 16.6 months between initial treatment and retreatment; Phase 3 AURORA topline data are expected in 1Q27 and a BLA filing in mid-2027.
1. Retreatment data
Cartesian Therapeutics said Descartes-08 showed a mean MG-ADL reduction of 6.6 points at month 12 after retreatment, with a median 16.6 months between initial treatment and retreatment infusion. The company reported no new safety signals and said the safety profile was consistent with previous data.
